Edap Tms S.A. (NASDAQ:EDAP) Short Interest Up 20.6% in March

Key Points

• Short interest up 20.6% — short interest rose to 56,032 shares as of March 31 (from 46,459 on March 15), equal to 0.2% of shares and a short-interest ratio of 1.5 days.
• Edap missed quarterly EPS (−$0.25 vs. −$0.16 expected) despite beating revenue ($22.22M vs. $21.28M), with negative ROE and a −41.24% net margin; analysts hold a consensus "Hold" with an average price target of $6 and several recent downgrades or lower targets.
• The stock traded down 2.8% to $3.49 (market cap ≈ $130.8M) and is largely institutionally owned (≈62.7%), with recent notable inflows including a roughly $2.6M stake by Flax Pond Capital.

Edap Tms S.A. (NASDAQ:EDAP - Get Free Report) was the recipient of a significant increase in short interest in March. As of March 31st, there was short interest totaling 56,032 shares, an increase of 20.6% from the March 15th total of 46,459 shares. Currently, 0.2% of the company's shares are short sold. Based on an average trading volume of 37,347 shares, the short-interest ratio is currently 1.5 days.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on EDAP shares. HC Wainwright lowered their price target on Edap Tms from $14.00 to $10.00 and set a "buy" rating for the company in a report on Thursday, April 9th. Wall Street Zen cut Edap Tms from a "hold" rating to a "sell" rating in a research note on Saturday, March 28th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Edap Tms in a report on Monday, December 29th. One research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $6.00.

Edap Tms Stock Down 2.8%

Shares of Edap Tms stock traded down $0.10 during trading on Friday, reaching $3.49. The stock had a trading volume of 50,261 shares, compared to its average volume of 62,306. The company has a market capitalization of $130.81 million, a price-to-earnings ratio of -4.53 and a beta of -0.09. The stock has a fifty day moving average price of $4.05 and a two-hundred day moving average price of $3.25. Edap Tms has a 52 week low of $1.21 and a 52 week high of $5.05. The company has a current ratio of 1.54, a quick ratio of 1.19 and a debt-to-equity ratio of 0.84.

Edap Tms (NASDAQ:EDAP - Get Free Report) last posted its quarterly earnings data on Wednesday, March 25th. The medical equipment provider reported ($0.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.09). The firm had revenue of $22.22 million for the quarter, compared to the consensus estimate of $21.28 million. Edap Tms had a negative return on equity of 100.07% and a negative net margin of 41.24%. Sell-side analysts predict that Edap Tms will post -0.6 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the business. Financial Planning Navigators CORP bought a new position in Edap Tms in the fourth quarter valued at $33,000. Leonteq Securities AG acquired a new position in shares of Edap Tms during the 4th quarter worth about $313,000. Kovack Advisors Inc. bought a new position in shares of Edap Tms in the 4th quarter valued at about $53,000. Rock Springs Capital Management LP increased its position in shares of Edap Tms by 1.3% in the fourth quarter. Rock Springs Capital Management LP now owns 1,286,500 shares of the medical equipment provider's stock valued at $4,233,000 after acquiring an additional 16,500 shares during the last quarter. Finally, Flax Pond Capital LLC bought a new stake in Edap Tms during the fourth quarter worth about $2,623,000. Institutional investors and hedge funds own 62.74% of the company's stock.

Edap Tms Company Profile

Edap Tms SA NASDAQ: EDAP is a Lyon, France–based medical device company that develops and markets noninvasive therapeutic systems for urological applications. The firm's core focus lies in high-intensity focused ultrasound (HIFU) for localized prostate tissue ablation and extracorporeal shock-wave lithotripsy for kidney stone fragmentation. Edap Tms's Ablatherm HIFU platform delivers targeted ultrasound energy to treat prostate cancer without incisions, while its Sonolith line offers pulse-focused shock waves designed to break down urinary calculi.

Since its founding in 1989, Edap Tms has pursued regulatory clearances in multiple markets, including CE marking in Europe and FDA clearance for its HIFU system in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.